Drug Abuse Test Kit Lysergic Acid Rapid Test 3mm strip ,high sensitivity cut-off 20ng/ml
Product Name
LSD ( Lysergic Acid) Rapid Diagnostic Test
Specimen: Urine
Background
Lysergic acid diethylamide (LSD) is a white powder or a clear,
colorless liquid. LSD is manufactured from lysergic acid which
occurs naturally in the ergot fungus that grows on wheat and rye.
It is a Schedule I controlled substance, available in liquid,
powder, tablet (microdots), and capsule form. LSD is recreationally
used as a hallucinogen for its ability to alter human perception
and mood. LSD is primarily used by oral administration, but can be
inhaled, injected, and transdermally applied. LSD is a
non-selective 5-HT agonist, may exert its hallucinogenic effect by
interacting with 5-HT 2A receptors as a partial agonist and
modulating the NMDA receptor-mediated sensory, perceptual,
affective and cognitive processes. LSD mimics 5-HT at 5-HT 1A
receptors, producing a marked slowing of the firing rate of
serotonergic neurons. LSD has a plasma half-life of 2.5-4 hours.
Metabolites of LSD include N-desmethyl-LSD, hydroxy-LSD, 2-oxo-LSD,
and 2-oxo-3-hydroxy-LSD .These metabolites are all inactive. LSD
use can typically be detected in urine for periods of 2-5 days.
The LSD Rapid Test Panel (Urine) is a rapid urine screening test
that can be performed without the use of an instrument. The test
utilizes a monoclonal antibody to selectively detect elevated
levels of Lysergic Acid Diethylamide in urine. The LSD Rapid Test
Panel (Urine) yields a positive result when Lysergic Acid
Diethylamide in urine exceeds 20 ng/mL.
Test Principle
The FYL Rapid Test Cassette (Urine) is an immunoassay based on the
principle of competitive binding. Drugs which may be present in the
urine specimen compete against the drug conjugate for binding sites
on the antibody.
During testing, a urine specimen migrates upward by capillary
action. Fentanyl, if present in the urine specimen below 20 ng/mL,
will not saturate the binding sites of antibody-coated particles in
the test device. The antibody-coated particles will then be
captured by immobilized FYL conjugate and a visible colored line
will show up in the test line region. The colored line will not
form in the test line region if the FYL level exceeds 20 ng/mL
because it will saturate all the binding sites of anti-FYL
antibodies.
A drug-positive urine specimen will not generate a colored line in
the test line region, while a drug-negative urine specimen or a
specimen containing a drug concentration less than the cut-off will
generate a line in the test line region. To serve as a procedural
control, a colored line will always appear at the control line
region indicating that proper volume of specimen has been added and
membrane wicking has occurred.
SPECIMEN COLLECTION AND STORAGE
The urine specimen must be collected in a clean and dry container.
Urine collected at any time of the day may be used. Urine specimens
exhibiting visible particles should be centrifuged, filtered, or
allowed to settle to obtain clear specimen for testing. Specimen.
Urine specimens may be stored at 2-8°C for up to 48 hours prior to
testing. For long-term storage, specimens may be frozen and stored
below -20°C. Frozen specimens should be thawed and mixed before
testing.
STORAGE
Store as packaged in the sealed pouch either at room temperature or
refrigerated (2-30°C). The test is stable through the expiration
date printed on the sealed pouch. The test must remain in the
sealed pouch until use. DO NOT FREEZE. Do not use beyond the
expiration date.
LIMITATION
1. The 6-MAM Rapid Test Cassette provides only a qualitative,
preliminary analytical result. A secondary analytical method must
be used to obtain a confirmed result. Gas chromatography/mass
spectrophotometry (GC/MS) is the preferred confirmatory method2.3.
2. It is possible that technical or procedural errors, as well as
other interfering substances in the urine specimen may cause
erroneous results.
3. Adulterants, such as bleach and/or alum, in urine specimens may
produce erroneous results regardless of the analytical method used.
If adulteration is suspected, the test should be repeated with
another urine specimen.
4. A positive result indicates presence of the drug or its
metabolites but does not indicate level of intoxication,
administration route or concentration in urine.
5. A negative result may not necessarily indicate drug-free urine.
Negative results can be obtained when drug is present but below the
cut-off level of the test.
performance characteristics
A side-by-side comparison was conducted using the Rapid Test
Cassette (Urine) and GC/MS. The following results were tabulated:
| Norfentanyl | Percent of | n | Visual Result |
| Concentration (ng/mL) | Cut-off | Negative | Positive |
|
| 0 | 0% | 30 | 30 | 0 |
| 10 | -50% | 30 | 30 | 0 |
| 15 | -25% | 30 | 27 | 3 |
| 20 | Cut-off | 30 | 15 | 15 |
| 25 | +25% | 30 | 3 | 27 |
| 30 | +50% | 30 | 0 | 30 |
| 60 | +300% | 30 | 0 | 30 |
| Analytical Specificity | | |
| ORIENT NEW LIFE MEDICAL CO., LTD. |
| Contact: | Jerry Meng |
| Email: | Jerry @ newlifebiotest .com |
| Tel. | +86 18657312116 |
| SKYPE | enetjerry |
